Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.
adolescents
adverse events
anti-obesity medication
body mass index
meta-analysis
obesity
Journal
Pediatric obesity
ISSN: 2047-6310
Titre abrégé: Pediatr Obes
Pays: England
ID NLM: 101572033
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
revised:
13
02
2024
received:
29
09
2023
accepted:
19
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
The effectiveness of anti-obesity medications for children and adolescents is unclear. To update the evidence on the benefits and harms of anti-obesity medication. Cochrane CENTRAL, MEDLINE, ClinicalTrials.gov and WHO ICTRP (1/1/16-17/3/23). Randomized controlled trials ≥6 months in people <19 years living with obesity. Screening, data extraction and quality assessment conducted in duplicate, independently. Body mass index (BMI): 95th percentile BMI, adverse events and quality of life. Thirty-five trials (N = 4331), follow-up: 6-24 months; age: 8.8-16.3 years; BMI: 26.2-41.7 kg/m Anti-obesity medications in addition to behaviour change improve BMI but may require dose adjustment, with 1 in 100 adolescents experiencing a serious adverse event.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13113Informations de copyright
© 2024 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London, England). 2017;390(10113):2627-2642. doi:10.1016/s0140-6736(17)32129-3
Anderson LN, Yoshida-Montezuma Y, Dewart N, et al. Obesity and weight change during the COVID-19 pandemic in children and adults: a systematic review and meta-analysis. Obes Rev. 2023; 24(5):e13550. doi:10.1111/obr.13550
Pineda E, Sanchez-Romero LM, Brown M, et al. Forecasting future trends in obesity across Europe: the value of improving surveillance. Obes Facts. 2018;11(5):360-371. doi:10.1159/000492115
Fryar CD, Carroll MD, Ogden CL. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2-19 years: United States, 1963-1965 through 2015-2016. https://www.cdc.gov/nchs/data/hestat/obesity_child_15_16/obesity_child_15_16.pdf
Sharma V, Coleman S, Nixon J, et al. A systematic review and meta-analysis estimating the population prevalence of comorbidities in children and adolescents aged 5 to 18 years. Obes Rev. 2019;20(10):1341-1349. doi:10.1111/obr.12904
Spinelli A, Buoncristiano M, Kovacs VA, et al. Prevalence of severe obesity among primary school children in 21 European countries. Obes Facts. 2019;12(2):244-258. doi:10.1159/000500436
Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol. 2021;9(7):418. doi:10.1016/S2213-8587(21)00145-5
World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. World Health Organization; 2000.
Ward ZJ, Long MW, Resch SC, Giles CM, Cradock AL, Gortmaker SL. Simulation of growth trajectories of childhood obesity into adulthood. N Engl J Med. 2017;377(22):2145-2153. doi:10.1056/NEJMoa1703860
Ells LJ, Rees K, Brown T, et al. Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews. Int J Obes. 2018;42(11):1823-1833. doi:10.1038/s41366-018-0230-y
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
Axon E, Atkinson G, Richter B, et al. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database Syst Rev. 2016;11(11):CD012436. doi:10.1002/14651858.CD012436
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406. doi:10.1016/j.jclinepi.2010.07.015
Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39. doi:10.1186/s13643-020-01542-z
Ahuja B, Klassen AF, Satz R, et al. A review of patient-reported outcomes for children and adolescents with obesity. Qual Life Res. 2014;23(3):759-770. doi:10.1007/s11136-013-0459-9
Foster BA, Winkler P, Weinstein K, Parra-Medina D. Developing a patient-centered outcome for targeting early childhood obesity across multiple stakeholders. BMC Obesity. 2018;5:39. doi:10.1186/s40608-018-0216-2
Halford JCG, Bereket A, Bin-Abbas B, et al. Misalignment among adolescents living with obesity, caregivers, and healthcare professionals: ACTION teens global survey study. Pediatr Obes. 2022;17(11):e12957. doi:10.1111/ijpo.12957
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
Ryder JRKA, Freedman DS. Metrics matter: toward consensus reporting of BMI and weight-related outcomes in pediatric obesity clinical trials. Obesity. 2022;30:571-572. doi:10.1002/oby.23346
de Vries CEE, Terwee CB, Al Nawas M, et al. Outcomes of the first global multidisciplinary consensus meeting including persons living with obesity to standardize patient-reported outcome measurement in obesity treatment research. Obes Rev. 2022;23(8):e13452. doi:10.1111/obr.13452
Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158-172. doi:10.1016/j.jclinepi.2012.01.012
Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66(2):173-183. doi:10.1016/j.jclinepi.2012.08.001
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. doi:10.1111/j.0006-341x.2000.00455.x
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629
Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials. 2007;4(3):245-253. doi:10.1177/1740774507079441
Olkin I, Dahabreh IJ, Trikalinos TA. GOSH - a graphical display of study heterogeneity. Res Synth Methods. 2012;3(3):214-223. doi:10.1002/jrsm.1053
Maier M, Bartoš F, Wagenmakers EJ. Robust Bayesian meta-analysis: addressing publication bias with model-averaging. Psychol Methods. 2023;28(1):107-122. doi:10.1037/met0000405
NCT02273804. Topiramate and Severe Obesity (TOBI). Accessed 04-17, 2023 https://clinicaltrials.gov/ct2/show/NCT02273804
NCT03338296. Study to evaluate the efficacy and Safety of Belviq XR® in conjunction with lifestyle modification for weight loss in obese adolescents, Age 12 to 17 Years. Accessed 17-04, 2023 https://clinicaltrials.gov/ct2/show/results/NCT03338296
Clarson CL, Brown HK, De Jesus S, et al. Effects of a comprehensive, intensive lifestyle intervention combined with metformin extended release in obese adolescents. Int Sch Res Notices. 2014;2014:659410:1-13. doi:10.1155/2014/659410
Fox CK, Kaizer AM, Rudser KD, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity. 2016;24(12):2553-2561. doi:10.1002/oby.21633
van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6(8):e228. doi:10.1038/nutd.2016.37
Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, et al. Metformin for obesity in Prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017;140(1):e20164285. doi:10.1542/peds.2016-4285
Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the Management of Childhood Obesity: a randomized control trial. Child Obes. 2018;14(8):553-565. doi:10.1089/chi.2018.0043
Bassols J, Martínez-Calcerrada JM, Osiniri I, et al. Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: a pilot study. PLoS One. 2019;14(12):e0226303. doi:10.1371/journal.pone.0226303
Li W, Li M, Kong D. Clinical efficacy of metformin combined with lifestyle intervention for treatment of childhood obesity with hyperinsulinemia. Int J Clin Exp Med. 2019;12(6):7644-7650.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of Liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128. doi:10.1056/NEJMoa1916038
Weghuber D, Forslund A, Ahlström H, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020;15(7):e12624. doi:10.1111/ijpo.12624
Fox CK, Clark JM, Rudser KD, et al. Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial. Obesity. 2022;30(5):1105-1115. doi:10.1002/oby.23395
Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/Topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6): EVIDoa2200014.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly Semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245-2257. doi:10.1056/NEJMoa2208601
Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21(4):339-348. doi:10.1515/jpem.2008.21.4.339
Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145(2):81-90. doi:10.7326/0003-4819-145-2-200607180-00005
Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289(14):1805-1812. doi:10.1001/jama.289.14.1805
Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873-2883. doi:10.1001/jama.293.23.2873
Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009;36(1):141-146. doi:10.1007/s12020-009-9196-9
Franco RR, Cominato L, Damiani D. The effect of sibutramine on weight loss in obese adolescents. Arq Bras Endocrinol Metabol. 2014;58(3):243-250. O Efeito da Sibutramina na Perda de Peso de Adolescentes Obesos. doi:10.1590/0004-2730000002825
Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4):E55. doi:10.1542/peds.107.4.e55
García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2006;28(5):770-782. doi:10.1016/j.clinthera.2006.05.008
Al G-M, Carraro L, Vieira A, et al. Treatment of obese adolescents with Sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90(3):1460-1465. doi:10.1210/jc.2004-0263
Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013;98(1):322-329. doi:10.1210/jc.2012-2710
Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18-28. doi:10.4158/ep.12.1.18
Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance-effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25(1-2):33-40. doi:10.1515/jpem-2011-0450
Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738-741. doi:10.1007/s00431-004-1534-6
Prado A, Gaete P, Corona H, Peralta E, Donoso A, Raimann T. Metabolic effect of metformin in obese adolescents at risk of diabetes mellitus type 2. Rev Chil Pediatr-Chile. 2012;83(1):48-57.
Rezvanian H, Hashemipour M, Kelishadi R, Tavakoli N, Poursafa P. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr. 2010;6(4):317-322. doi:10.1007/s12519-010-0232-x
Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91(6):2074-2080.
van Mil EG, Westerterp KR, Kester AD, Delemarre-van de Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolescents. J Clin Endocrinol Metab. 2007;92(4):1409-1414.
Wiegand S, L'Allemand D, Hübel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163(4):585-592. doi:10.1530/eje-10-0570
Wilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010;164(2):116-123. doi:10.1001/archpediatrics.2009.264
Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011;60(2):477-485. doi:10.2337/db10-1185
NCT00001723. Safety and Efficacy of Xenical in Children and Adolescents with Obesity-Related Diseases. Accessed 12-19, 2023 https://clinicaltrials.gov/ct2/show/NCT00001723
O'Connor E EC, Henninger M, Redmond N, Senger C, Thomas R. Evidence Synthesis Number 237 Interventions for High Body Mass Index in Children and Adolescents: an Evidence Update for the U.S. Preventive Services Task Force 2023. AHRQ Publication No 23-05310-EF-1. https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/high-body-mass-index-children-adolescents-interventions
El-Medany AYM, Birch L, Hunt LP, et al. What change in body mass index is required to improve cardiovascular outcomes in childhood and adolescent obesity through lifestyle interventions: a meta-regression. Child Obes. 2020;16(7):449-478. doi:10.1089/chi.2019.0286
Rajjo TAJ, Al Nofal A, Farah W, et al. The association of weight loss and cardiometabolic outcomes in obese children: systematic review and meta-regression. J Clin Endocrinol Metab. 2017;102(3):758-762. doi:10.1210/jc.2016-2575
Aronne LJSN, Horn DB, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2023;331:38. doi:10.1001/jama.2023.24945
Fu RGG, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. methods guide for effectiveness and comparative effectiveness reviews. agency for healthcare research and quality. 2010.
Kelly AS, Arslanian S, Hesse D, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity. 2023;31:2139-2149. doi:10.1002/oby.23808
Young KG, McInnes EH, Massey RJ, et al. Precision medicine in type 2 diabetes: a systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors. medRxiv. 2023. doi:10.1101/2023.04.21.23288868
Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in response to treatment of adolescents with severe obesity: the need for precision obesity medicine. Obesity. 2019;27(2):288-294. doi:10.1002/oby.22369
US Preventive Services Task Force; Grossman DC B-DK, Curry SJ, Barry MJ, et al. Screening for obesity in children and adolescents: US preventive services task force recommendation statement. JAMA. 2017;317(23):2417-2426. doi:10.1001/jama.2017.6803
Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021;22(6):e13177. doi:10.1111/obr.13177
Cornejo-Estrada A, Nieto-Rodríguez C, León-Figueroa DA, Moreno-Ramos E, Cabanillas-Ramirez C, Barboza JJ. Efficacy of Liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials. Children. 2023;10(2):208. doi:10.3390/children10020208
Hui F, Zhang Y, Ren T, Li X, Zhao M, Zhao Q. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2019;75(4):437-450. doi:10.1007/s00228-018-2593-3
Lentferink YE, Knibbe CAJ, van der Vorst MMJ. Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review. Drugs. 2018;78(18):1887-1901. doi:10.1007/s40265-018-1025-0
Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB. Efficacy and safety of metformin for obesity: a systematic review. Pediatrics. 2021;147(3):e20201610. doi:10.1542/peds.2020-1610
Ryan PM, Seltzer S, Hayward NE, Rodriguez DA, Sless RT, Hawkes CP. Safety and efficacy of glucagon-like Peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J Pediatr. 2021;236:137-147.e13. doi:10.1016/j.jpeds.2021.05.009
Sadeghi A, Mousavi SM, Mokhtari T, Parohan M, Milajerdi A. Metformin therapy reduces obesity indices in children and adolescents: a systematic review and meta-analysis of randomized clinical trials. Child Obes. 2020;16(3):174-191. doi:10.1089/chi.2019.0040
Sun J, Wang Y, Zhang X, He H. The effects of metformin on insulin resistance in overweight or obese children and adolescents: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine. 2019;98(4):e14249. doi:10.1097/md.0000000000014249
Zhao G, Zhang Q, Wu F, Yin S, Xie Y, Liu H. Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2022;15(9):1119-1125. doi:10.1080/17512433.2022.2117152
FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine). Accessed 04-06, 2023 https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-continued-use-meridia-sibutramine
FDA approves weight management drug for patients aged 12 and older. 2023 https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older#:~:text=%5B12%2F4%2F2020%5D,30%20kg%2Fm2%20or%20higher
Assessment report: Saxenda. 2021 https://www.ema.europa.eu/en/documents/variation-report/saxenda-h-c-3780-ii-0026-epar-assessment-report-variation_en.pdf
Refusal of the marketing authorisation for Qsiva (phentermine / topiramate). Accessed 11-30, 2022 https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-qsiva-phentermine/topiramate_en.pdf
FDA approves treatment for chronic weight management in pediatric patients aged 12 years and older. Accessed 11-30, 2022 https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-chronic-weight-management-pediatric-patients-aged-12-years-and-older#:~:text=The%20U.S.%20Food%20and%20Drug,or%20greater%20when%20standardized%20for
FDA approves once-weekly Wegovy® injection for the treatment of obesity in teens aged 12 years and older. Accessed 10-01, 2023 https://www.novonordisk-us.com/media/news-archive/news-details.html?id=151389
European Medicines Agency. Wegovy. Accessed 06-07, 2023 https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-wegovy-ii-09_en.pdf
Srivastava G, Fox CK, Kelly AS, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity. 2019;27(2):190-204. doi:10.1002/oby.22385
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi:10.1016/j.eclinm.2023.101882
NCT04775082. SCALE KIDS: Research study to look at how well a new medicine is at lowering weight in children with obesity. Accessed 06-13, 2023 https://clinicaltrials.gov/ct2/show/NCT04775082
NCT05726227. A Research Study on how Well Semaglutide Helps Children and Teenagers with Excess Body Weight Lose Weight (STEP Young). Accessed 06-13, 2023 https://clinicaltrials.gov/ct2/show/NCT05726227
NCT04678323. Pharmacotherapy for Pediatric Obesity: A Phentermine Clinical Trial. Accessed 06-13, 2023 https://clinicaltrials.gov/ct2/show/NCT04678323
Mazur A, Zachurzok A, Baran J, et al. Childhood obesity: position statement of polish Society of Pediatrics, polish Society for Pediatric Obesity, polish Society of Pediatric Endocrinology and Diabetes, the College of Family Physicians in Poland and polish Association for Study on obesity. Nutrients. 2022;14(18):3806. doi:10.3390/nu14183806
Fallows E, Ells L, Anand V. Semaglutide and the future of obesity care in the UK. Lancet. 2023; 401(10394):2093-2096. doi:10.1016/s0140-6736(23)01083-8
Moore JNJ, Li K, Inge T, Boles R, Kelsey M. Phentermine/topiramate after adolescent bariatric surgery shows feasibility and initial efficacy. Obesity. 2021;29(2):31. doi:10.1002/oby.23328
NCT04095104. Adjunct Phentermine + Topiramate after Bariatric Surgery in 12-24 Year Olds. Accessed 12-19, 2019 https://clinicaltrials.gov/ct2/show/NCT04095104
Bann D, Johnson W, Li L, Kuh D, Hardy R. Socioeconomic inequalities in childhood and adolescent body-mass index, weight, and height from 1953 to 2015: an analysis of four longitudinal, observational, British birth cohort studies. Lancet Public Health. 2018;3(4):e194-e203. doi:10.1016/s2468-2667(18)30045-8
Hoebel J, Waldhauer J, Blume M, Schienkiewitz A. Trends of socioeconomic inequalities in overweight and obesity in children and adolescents in Germany. Eur J Pub Health. 2022;32(Supplement_3):ckac130.076. doi:10.1093/eurpub/ckac130.076
Traore SS, Bo Y, Kou G, Lyu Q. Socioeconomic inequality in overweight/obesity among US children: NHANES 2001 to 2018. Front Pediatr. 2023;11:1082558. doi:10.3389/fped.2023.1082558
Lobstein T, Neveux M, Brown T, et al. Social disparities in obesity treatment for children age 3-10 years: a systematic review. Obes Rev. 2021;22(2):e13153. doi:10.1111/obr.13153
Ball G, Bridger T, Chanoine J, et al. 5As of pediatric obesity management. Accessed 03-08, 2023 https://obesitycanada.ca/wpcontent/uploads/2018/02/Pediatric_5As_Practitioner_Guide_WM.pdf
Ells LJ, Ashton M, Li R, et al. Can we deliver person-Centred obesity care across the globe? Curr Obes Rep. 2022;11(4):350-355. doi:10.1007/s13679-022-00489-7
Hampl SEHS, Skinner AC, Armstrong SC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
Floegel-Shetty A. Should pharmaceuticals be used as weight loss interventions for adolescents classified as obese by BMI? AMA J Ethics. 2023;25(7):E478-E495. doi:10.1001/amajethics.2023.478
Lister NBBL, Felix JF, Hill AJ2, et al. Child and adolescent obesity. Nat Rev Dis Primers. 2023;9(24):24. doi:10.1038/s41572-023-00435-4